Cinoxacin

Summary

Cinoxacin (CHEMBL1208) is an approved small-molecule antibacterial drug (ATC J01MB06); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MB06
• Indications: 2 conditions
• Chemistry: 262.22 Da · C12H10N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1208
Name	Cinoxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2762
ChEBI	CHEBI:3716
ATC	J01MB06
Molecular formula	C12H10N2O5
Molecular weight	262.22
InChIKey	VDUWPHTZYNWKRN-UHFFFAOYSA-N

SMILES: CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3

IUPAC name: 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid

ChEBI definition: A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.

Pharmacological roles (ChEBI): antibacterial drug, antiinfective agent.

Also known as: Cinobac, Cinoxacin, Cinoxacine, Cinoxacino, NSC-304467, SID11110995, SID11110996, SID50104192, SID50104193, SID85230984, SID855948, SID90341598

Patent coverage: 2,975 distinct patent families (11,109 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,036 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, RecQ-like DNA helicase BLM, Peripheral myelin protein 22, Thyrotropin receptor, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 11 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.3	Potency	5	nM	CHEMBL_ACT_3651813
BLM	6.55	Potency	281.8	nM	CHEMBL_ACT_4745916
BLM	6.55	Potency	281.8	nM	CHEMBL_ACT_4921908
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_3912317
TSHR	5.1	Potency	7943	nM	CHEMBL_ACT_4718995

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).